
Fluidigm Corporation FLDM
Fluidigm Corporation Book Value 2011-2026 | FLDM
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Fluidigm Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 132 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 132 M | 132 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.73 | -1.86 % | $ 61.9 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 29.0 | -3.07 % | $ 316 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 23.87 | -0.13 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
116 M | $ 104.95 | -1.72 % | $ 4.14 B | ||
|
Co-Diagnostics
CODX
|
86 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
456 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
2.75 B | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
261 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
6.3 B | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
-2.22 M | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 169.68 | 3.11 % | $ 8.41 B | ||
|
IDEXX Laboratories
IDXX
|
1.6 B | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
6.63 B | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Koninklijke Philips N.V.
PHG
|
12 B | $ 31.19 | 0.73 % | $ 20 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Quidel Corporation
QDEL
|
11.9 B | $ 22.47 | -4.85 % | $ 947 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.07 B | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
221 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
National Research Corporation
NRC
|
49 M | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 378.44 | 0.14 % | $ 28.4 B |